Table Of Content

PRIMARY Prim Care Clin Office Pract CARE 30 (2003) 821-845 Cumulative Index 2003 Volume 30 March UPDATE ON INFECTIOUS DISEASES, pages 1-248 June OBESITY, pages 249-498 September ENDOCRINOLOGY PART DIABETES, pages 499-624 December ENDOCRINOLOGY PART GENERAL ENDOCRINOLOGY pages 625-846 Vote: Page numbers of article titles are in boldface type A Adrenal gland Abdominal adipose tissue, measurement of insufficiency 601—602? 257-258 tumors ol Abdominal pressure, increased, in obesity, 349 Abscess perinephric, 50 renal. 50 tubo-ovarian, 197-198 4C2993 (exendin-4), for diabetes mellitus Adrenal vein sampling 477 hyperaldoste1 Acarbose, for diabetes mellitus, 469, 472, Adrenocorticotropic | 529, 53! deficiency of, a preventive, 518-519 treatment ectopic secret Acne, in polycystic ovary syndrome, 697 syndrome 702 measurement syndrome Acquired immunodeficiency syndrome. See Human immunodeficiency virus ymonas,in bite v infection. Age, Body Size. No | Acromegaly, in pituitary tumors, 77 (ABONE) 711-712, 714 ACTH. See Adrenocorticotropic hormone AIDS. See Humar infection Acupuncture, for menopausal symptoms, 670 Aldosterone, excess Hyperaldostet Acute coronary syndrome, dyslipidemia in, treatment of, 653-654 Aldosterone:renin rati hyperaldosteron Acyclovir, for genital herpes, 180, 196-197 Alendronate, for os Adenoidectomy, for sleep apnea, 364 in corticoster therapy, 600 Adenomas, pituitary. See Pituitary tumors. postmenopausal, 676-67 0095-4543/03/$ - see front matter © 2003 Elsevier Inc. All rights reserved doi: 10.1016/S0095-4543(03)00109-X 822 Cumulative Index | Prim Care Clin Office Pract 30 (2003) 821-845 Alkaline phosphatase, as bone turnover Animal bite wound infections. See Bite marker, 717 wound infections Allergic reactions, otitis media in, 110-111 Anorexia in hepatitis A, 86 Alopecia, in polycystic ovary syndrome, 697 in hepatitis E, 87 in otitis media, 112 Alpha-glucosidase inhibitors, for diabetes mellitus, 466-467, 469, 529, 535 Anthropometry, 2 Alternative medicine. See also Herbal Antibiotics. See also specific antibiotics preparations. colitis associated with, 74-79 for menopausal symptoms, 670-671 for bite wounds, 34-36 for pneumonia, 156-165 Alveolar macrophages, in pneumonia resistance to defense, 151—152 in Neisseria gonorrhoeae, 194 in Otitis media organisms. Alzheimer’s disease, prevention of, hormone 120-121 therapy for, 679-680 in pneumonia, 157 Amenorrhea in rhinosinusitis, 139-140 in polycystic ovary syndrome, 697, 703 Antiestrogens, for hirsutism, in polycystic in prolactinoma, 767 ovary syndrome, 703-704 American Diabetes Association, diabetes Antihistamines, for otitis media prevention. definition of, 499, 501 128 Aminotransferases, in hepatitis, 81-82 Antiretroviral therapy, for HIV, 220-223, 996997 Ammonium sulfate procedure, for testosterone measurement, 745 Anxiety, versus pheochromocytoma, 806 Amoxicillin Apnea, sleep. in obesity, 296-297, 347, 349 for Chlamydia trachomatis infections, in pediatric patients, 363-365 193 for otitis media, 115-116, 122 Aspirin, in cardiovascular disease for scarlet fever, 12 prevention, in diabetes mellitus, 586-587 for urinary tract infections, 44 Amoxicillin-clavulanate Asthma, risk of, in hormone therapy, for bite wound infections, 35 Atherosclerosis for rhinosinusitis. 140 in hypothyroidism, 626-627 for urinary tract infections, 54 in polycystic ovary syndrome, 700-701 Ampicillin, for bite wound infections, 3: obesity and, 346-347 Anaerobic infections bite wound, 26-31 Athlete’s foot (tinea pedis), 15-17 pneumonia, 158 Atorvastatin, for dyslipidemia, 654. 657-658 Anal warts. 180-183, 196 Androgen(s) Atrial fibrillation excess of, in polycystic ovary in hyperthyroidism, 632 syndrome, 696-700 in hypothyroidism overtreatment, 627 replacement therapy with, for Atypical diabetes mellitus, 500, 502 hypogonadism, 749-758 Autoantibodies, in diabetes mellitus, Andropause, treatment of, 749, 751 501-502 Angina, Ludwig's, 7-8 Azithromycin Angina pectoris, diabetes mellitus in, for Chlamydia trachomatis infections, 193 563-564 for gonorrhea, 193 Angiotensin-converting enzyme inhibitors, for otitis media, 123, 125 for diabetes mellitus prevention, 520 for rhinosinusitis, 140 Cumulative Index | Prim Care Clin Office Pract 30 B Bite wound infections, 25-39 Bacitracin, for impetigo, | complication 3 diagnosis ol Bacteremia, in urinary catheter-associated epidemiology infections, 52-53 microbiolog Bacterial vaginosis, 189-190 path} ogenesis treatment ol Bacteriuria, asymptomatic, 51 in elderly persons, 48—49 Black cohosh in pediatric patients, 55 671 in pregnancy, 53 Bladder infect Bacteroides infections, bite wound, 26-29 women Bariatric surgery Blood pressure for diabetes mellitus prevention, elevated. Se 5? 1 $79 hormone th for obesity, in diabetes mellitus, measurement 478-481 Body composition, 249-265 Behavioral techniques, for obesity fat mass, 250 $2 treatment, 375-390 Measureime adherence strategies in, 382-383 barriers to, 387 clinical applications of, 380-388 dietary recommendations in, 381-382 environm: tal modifications in, 386-387 exercise for, 383-385 format for, 380-381 goals of, 381 in social settings, 387 negative thinking in, 387 overview of, 380 planning for lapses, 388 research on, effectiveness of, 375 self-monitoring in, 385-386 Beta-blockers, with insulin, in diabetes mellitus. 612-614 Beta cells, destruction of, in diabetes mellitus, 501—502 mass index Beverages, calorie content of, 306-307 calculation of Bichloroacetic acid, for genital warts, 183 lor pediatric pz 195-196 heart disease in obesity class Biguanides, for diabetes mellitus, 466-467. normal, 343 529, 534-535 Bone loss. See « Biochemical markers, for bone turnover, with weight 716-717 Bone mass density Bioimpedance analysis, for body a0 715 i composition, 253-254 Brain Biopsy, liver, in hepatitis B, 92 olillis Media 5] Bird bites and pecks, infections of, 31 pituitary tumor tumors Bisphosphonates, for osteoporosis, 719-720 in corticosteroid therapy, 600 Breast cancer, risk postmenopausal, 676-677 680-682 824 Cumulative Index | Prim Care Clin Office Pract 30 (2003) 821-845 Breastfeeding Captopril, for diabetes mellitus prevention, hyperprolactinemia in, 767 520 obesity in, 354 Carbuncles, 3-4 Brindall berry rinds, for obesity, 451-452 Cardiovascular disease. See also Coronary Bromocriptine artery disease for growth hormone-producing in diabetes mellitus, 569-592 pituitary tumors, 776 epidemiology of, 569-572 for prolactinoma, 769-772 in metabolic syndrome, 5 in pediatric patients, 573 Bronchospasm, risk of, in hormone therapy. mortality in, 569 683 prevention of anticoagulant therapy in, 585-58 C exercise in, 581, 584-585 food management in, 581, Cabergoline 584-585 for growth hormone-producing glucose elevation pituitary tumors. 776 for prolactinoma, 769-770 M5 anagS7e8m ent In, Caffeine, for weight loss, in herbal hyperlipidemia control in, preparations, 441-449 580-583 hypertension control in, Calcitonin, for osteoporosis. 600, 723, 727 $79—S580 Calcium supplementation tobacco use cessation in, for osteoporosis, 717-718, 721 $78 in corticosteroid therapy, 599 with multiple risk factors, Calicivirus infections, gastroenteritis, 73 Calories estimating of, 312 in hypothyroidism overtreatment, 627 in beverages, 306—307 in polycystic ovary syndrome, 700-701 in low-fat versus high-fat foods. prevention of, hormone therapy for, 305-306 677-679 Calpyte HIV-1” test. for HIV, 212 Cat bite wound infections. See Bite wound infections Campylobacter gastroenteritis, 67-68 Catechins, green tea, for obesity. 449-450 Cancer breast, risk for, in hormone therapy. Catecholamines, production of, in 680-682 pheochromocytoma, 803. 807-810 colorectal, prevention of. hormone Catheter-associated infections, urinary. therapy for, 677 52-53 endometrial, risk for. in hormone Cavernous sinus sampling, in Cushing's therapy, 680 syndrome, 792 in obesity, 295-296, 348 ovarian, risk for, in hormone therapy. Cefadroxil, for urinary tract infections, 44 682 Cefazolin, for erysipelas, 7 prostate, risk of, in androgen replacement, 754-755 Cefixime, for gonorrhea, 193 thyroid, hormone replacement in. Cefotetan, for pelvic inflammatory disease, 634-635 198 Candidiasis Cefoxitin, for pelvic inflammatory disease, oral, in HIV infection, 206—207 198 vulvovaginal, 190-191 Ceftizoxime, for gonorrhea, 194 Capnocytophaga, in bite wound infections, 26 Ceftriaxone for epididymitis, 178 Capsaicin, for obesity, 450 for gonorrhea, 193 Cumulative Index | Prim Care Clin Office Pract 30 ellulitis, 4—5 Clomiphene, for in diabetes mellitus, 565 polycystic ov necrotizing, 5-9 periorbital and orbital, 5 Clonidine. for enters for Dietary Supplement Research in Clonidine suppressi¢ Botanicals, 440 pheochromoc ephalexin, for urinary tract infections, 54 Clostridium d antibiotics assoc ephalosporins, resistance to, 120 cl1i: nical feSaet u erivastatin, for dyslipidemia, 657 diagnosis of, /¢ pathophvs ) ervicitis, in Chlamydia trachomatis risk factors infections, 192-193 treatment ervix, warts of, 195 heilitis, angular, in HIV infection, 206 hest radiography, in pneumonia, 152-153 Clotrimazole 19] hili peppers, capsaicin from, for obesity, 450 Coccidioid hinese medicine, for weight loss, 441-449 Colesevelam hitosan, for obesity, 454-455 Colestipo! hiamydia pneumoniae pneumonia, 159 Colitis, ¢ hlamydia trachomatis infections Clinical [e< epididymitis, 176 diagnosis « genital, in females, 192 119933 path1 ophy1 s urethritis, in men, 171-175 factors holera, 70-71 holesterol. See a/so Hypercholesterolemia obesity and, 293-295 holestyramine, for dyslipidemia, 647-648, 658-659 therapy) 1 ommunily-acc hromaftin cells, tumors of. See ao . Pheochromocytoma Pneumonia hromogranin A, in pheochromocytoma aan epi 808 Herbal prepat hylomicr.o nemia syndrome, 65<6 Compuptuteedc tomo in chi iprofloxacin, for gonorrhea, 193 n ¢ ircumcision, sexually transmitted in ¢ infections and, 184 in pheocht irrhosis in prolact in hepatitis B, 91 In rhinosinu in hepatitis C, 99, 10] : P Condylomata, 23 itrus aurantium, for obesity, 450 . Conn syndrome larithromycin, for rhinosinusitis, oronary artery lindamycin in diabete for bacterial vaginosis, 190 for necrotizing fascitis, 9 for pelvic inflamniatory disease, 198 lofibrate, for dyslipidemia, 661 826 Cumulative Index | Prim Care Clin Office Pract 30 (2003) 821-845 Coronary (continued ) in exogenous glucocorticoid hyperlipidemia control in, administration, 791 581 in pituitary tumors, 791—792 tobacco use cessation in, male hypogonadism in, 747-748 578 obesity in, 350 with multiple risk factors, versus pseudo-Cushing’s syndrome, 575, 577 789-790 in metabolic syndrome, 650 Cystic fibrosis, diabetes mellitus in, 502 in polycystic ovary syndrome, 700-701 prevention of, hormone therapy for, Cystitis 677-679 acute, uncomplicated, in women, risk factors for, 643 42-45 in men, 49 Corticosteroids recurrent, in women, 45 chronic use of, 593-605 adrenal insufficiency in, 601-602 dyslipidemia in, 600-601 hyperglycemia in, 594-598 D osteoporosis in, 598-600 Day care, as otitis media risk factor, 111 Cushing's syndrome from, 791 in diabetes mellitus, glucose control Decongestants and, 564-565 or Otitis media prevention, 128 replacement of, after pituitary tumor for rhinosinusitis, 140-141 treatment, 780 Deep venous thrombosis, hormone therapy effects on, 682 Corticotropin-releasing hormone test, in Cushing's syndrome, 790 Dementia, prevention of, hormone therapy for. 679-680 Cortisol excess of. See Cushing’s syndrome Depression, in menopause, hormone secretion of, in Cushing’s syndrome therapy for, 675 diagnosis, 789-790 Dexamethasone suppression test, for Cough, in pneumonia, 152 Cushing's syndrome, 789-790 Dexfenfluramine, for obesity, 447-448 Counseling, on HIV infection, 210-211, 777 298 Diabetes mellitus asymptomatic bacteriuria in, 51 Cranberry juice, for urinary tract infection atypical, 500, 502 prevention, 46 autoimmune beta-cell destruction in, 500—502 Cranial nerve deficits, in pituitary tumors. 764 cardiovascular disease prevention in, 569-592 Cryotherapy, for genital warts, 182, 195 classification of, 499-510 Culture corticosteroid-induced, 594-598 Clostridium difficile, 77 cystic fibrosis-related, 502 definition of, 499, 501 HIV, 213 urine, in urinary tract infections, diagnosis of, 522-523, 538 drug-induced, 594-598 43-44, 54-55 dyslipidemia in, treatment of, 649-652. Cushing’s syndrome, 787-795 660-661 ACTH dependent or ACTH gestational. 503 independent, 791 hormone therapy and, 680 adrenal imaging and surgery in, 791 in growth hormone-producing clinical presentation of, 788 pituitary tumors, 777 cortisol secretion measurement in, in obesity, 275, 288-290, 346, 463-489, 789-790 503, 537-539 dexamethasone suppression test in, antidiabetic agents for, 464-472 789-790 insulin, 470-472 diagnosis of, 787-793 oral, 465-470, 472 in ectopic ACTH secretion, 791-793 antiobesity therapy for, 472-481 Cumulative Index | Prim Care Clin Office Pract 30 (2003) 82 bariatric surgery, 478-481 Diarrhea caloric restriction, 473 in antibiotic-associa orlistat, 474, 476-477 in gastroenteritis. See sibutramine, 416-417, 474-476 Diazox7i0d4e , for polycystic epidemiology of, 463-464 in polycystic ovary syndrome, 699 Diet latent autoimmune, 500, 505—S507 lipodystrophic, 500, 508 r cardiovascula 581, 584-5 myths involving, 607-618 of young, maturity-onset (MODY). diabetes mell 512-517 500, 503-505 hpid-lowerin pancreatic, 500, 502 weight loss treatment of behaviora exercise adjustment in, ‘ 38 1—383. 387-388 gestational, 538 energy intake and, 309 hypoglycemia in, 550-55] herbal supplements for. See in nothing-by-mouth situation, Herbal preparations 554-555, 562-564 obesit\ in oral agent failure, 543, in diabetes mellitus. 473 546-547 individualized, 309 inpatient, 557-567 insulin in. See Insulin. Dietary Supplements He lifestyle interventions in, 527 herbal preparat 531-532 oral agents in. See Oral Diverticulitis, diabetes hypoglycemic agents. problems with, 543-556 DNA analysis, in HIV uncontrolled, 551—552 1, 500-502 Dog bite wound infection ‘i infections diagnosis of, versus type 2, 538 presentation of, in older patients, Don quai, for menopa | svmptoms, 6 608-609 type 1.5, 500, 505-507 Double (hybrid, type 3) diabetes mellitus 500. 507—S08 type 2, 500, 503 diagnosis of, versus type 1, Doxycycline 538 for Chlamydia prevention of, 511-526 192-193 bariatric surgery in, for epididymitis 521-522 for gonorrh candidates for, 522 523 for pelvic inflamm lifestyle interventions in, 512-517 Drug(s) pharmacologic hyperlipidemia from, 644, 646-647 interventions in, in HIV infection, 655-656 517-521 hyperprolactinemia risk factors for, 511, 522 weight gain relate treatment of, 547-550 Dual-energy x-ray absor in oral agent failure, 543, for body composition, 253, 255 546-547 for osteoporosis screening, 7 lifestyle interventions in, in corticoster« 527, 531-532 oral agents for. See Oral Dyslipidemia, 641-668 hypoglycemic agents; approach to, 641-646 specific agents assessment of, 642-643 type 3‘ (double, hybrid), 500, elevated LDL cholesterol, 644, 5 07-508 646-647. 649 fasting lipid profile in, 641-642 Diabetes Prevention Program, behavioral in acute coronary syndrome, 653-654 Pet tf approaches in, 375-3 in diabetes mellitus, 649-652 828 Cumulative Index | Prim Care Clin Office Pract 30 (2003) 821-845 Dyslipidemia (continued ) Enzyme-linked immunoassay in hypertriglyceridemia with HIV for Clostridium difficile, 76 infection, 654-656 for HIV, 211-212, 214 in hypothyroidism, 626-627, 630-631 Eosinophilia, in nasal polyposis, 146 in isolated low HDL cholesterol, 641, 652-653 EpIh edrine, for weig§ ht loss, in herbal in metabolic syndrome, 649-652 preparations, 441-449 in polycystic ovary syndrome, 700-701 obesity and, 293-294, 345-346 Epididymitis, 175-178 in pediatric patients, 368-371 Epinephrine, production of, in orlistat effects on, 428-429 pheochromocytoma, 803. 807-810 sibutramine effects on, 417-418 prevention of, hormone therapy for, Equilibrium dialysis, for testosterone 679 measurement, 745 treatment of, 643-646, 657-661 Erysipelas, 7 Dysmetabolic syndrome. See Metabolic Erythromycin syndrome. for Chlamydia trachomatis infections, 193 Dysuria, in cystitis, 43 for urinary tract infections, 54 Escherichia coli infections E gastroenteritis, 65-67 urinary tract, 43, 46 Ear infections. See Otitis media. Esophagitis, herpes simplex virus, diabetes Ectopic ACTH syndrome, 791-793 mellitus in, 562-563 Eikenella corrodens, in bite wound Estrogen(s) infections, 26, 35-36 for diabetes mellitus prevention, 521 Elderly persons, urinary tract infections in, for Os1t6eo.p7o2r7os ls, 719-720. 722 48-49 lipid-lowering effect of, 649 Elsinore Pill, for obesity, 443-444 replacement of. See Hormone Emphysematous pyelonephritis, 50-51 replacement therapy Endocrine disorders Ethnic factors, in diabetes mellitus, 502 male hypogonadism, 723-743 Etidronate, for osteoporosis, 723, 729-730 pituitary tumors, 745-767 polycystic ovary syndrome, 537-538, Eustachian tubes, dysfunction of, otitis 573-575, 695-708 media in, 108-109, 115 thyroid, 350, 625-640 Evening primrose oil. for menopausal Endometrial cancer. risk for. in hormone symptoms, 671 therapy. 680 Exendin-4, for diabetes mellitus, 477 Endometritis, 197—198 Exercise Endoscopy for cardiovascular disease prevention. in chronic rhinosinusitis, 143-144 in diabetes mellitus, 581, 584-585 in Clostridium difficile coiitis, 77 for diabetes mellitus prevention. 512-517 Energy density. of food, 306 for menopausal symptoms, 670 Enteroaggregative Escherichia coli for metabolic syndrome, 651 infections, 67 for obesity, 347-348, 383-385, 391-401 Enterobacteriaceae, in pneumonia, assessment before, 394-395 160-161 barriers to, 395 Enterohemorrhagic Escherichia coli continued patient contact infections, 67 concerning, 399 for weight gain primary Enterotoxigenic-producing Escherichia coli prevention, 392-339933 infections, 67 for weight loss. 391—392 Cumulative Index | Prim Care Clin Office Pract for weight regain prevention, Fiber, dietary, for 39] -392 > 1 ] 1 health impact of, 393 Fish bite wound intermittent versus continuous, Fish oil, for dysl ilpt d 397-398 . y 2 | le I lifestyle approaches to, 398-399 Fluconazole, for . . 202 207 9 prescription for, 393-39 = rate » ‘ec o %397—39¢ strategies affecting, 397-399 Fluoride, for osteop for osteoporosis, 721 insulin dose adjustment for, Fluoxetine, for me Fluvastatin, for dyslipider Follicle-stimulating ace, bite wound infections of, 34 measurement hypogot amciclovir, for genital herpes, 180. pituitary tun 196-197 asciilis, necrotizing, 8-9 Folliculitis, 3-4 asting, for weight loss, 310 Fi ood intake, obesi nd. 301-316, 352 Fat (body) pet apache conjugated linoleic acid effects on, c-aalolroirei e inc I 450-45] control strat distribution of conveneiReen ce at menopause, 319-321 energy dens estimation of, 33 44 fat it ccoonntteenntt morbidity and, 288 pyoorrtt ion dilsits tort morta; lity rate and, 285 —ug-ar- containi fat mass Foodborne gastroent percentage of, from skinfold Bacillus « ereu thickness, 252 Campylo} ba ‘ reference values for, 250 Clostridiun in liver, in obesity, 360-363 Escherichia total, at menopause, 318-321 in travelers Fat (dietary) Listeria mor absorption of,, orlistat inhib| ition of, Saalgmoane lla 436 Shigella, 69 in ceoams mon f7 oods 2] Stap| hylocos oc = Vibrio, 70 in weight loss diets 7: 172 intake of, 33 04-30WS5s, Virraal , < Ye rSsiild e@} atigue | : osfonmlycin, [or in hepatitis A, 86 ae in HIV infection, 204-205 Fractures, in osteopo atty disease, of liver, nonalcoholic, in Fungal infections obesity, 360-363 rhinosinusitis <in and subcu emales, genital tract infections in. See skin and st Genital tract infections, in females. Furuncles, 3-4 emur, slipped capital epiphysis of, in Fusobacterium, in bit obesity, 365—366 6-27. 30 enfluramine, for obesity, 447-448 Fenofibrate, for dyslipidemia, 658 G Fever Galactorrhea in hepatitis A, 86 in growth hormone-producing in HIV infection, 204-205 pituitary tumors, 772 in Otitis media, 112 in prolactinoma, 767-769 830 Cumulative Index | Prim Care Clin Office Pract 30 (2003) 821-845 Gallbladder disease uncontrolled, 552 in hormone therapy, 683 with hypoglycemia, 547 in obesity, 291-292, 348 Glitinides, for diabetes mellitus, 528, Garcinia cambogia (hydroxycitric acid), for 53 3-534 obesity, 451-452 Glucagon-like peptide, for diabetes mellitus, 477 Gardnerella vaginalis infections, 189-190 Gastroenteritis, 63-80 Glucocorticoids. See Corticosteroids Bacillus cereus, 72 Glucokinase, defects of, diabetes mellitus in, Campylobacter, 67-68 504 Clostridium perfringens, 71-72 epidemiology of, 63-64 Glucomannan, for obesity, 452-453 Escherichia coli, 65-67 Glucose intolerance, in polycystic ovary Listeria monocytogenes, 7\ syndrome, 699 pathogenesis of, 64-65 Salmonella, 68-69 Glucose tolerance, impaired, in obesity, 37 Shigella, 69-70 orlistat effects on, 429-431 Staphylococcus aureus, ya Glucose tolerance test, for pre-diabetes, 523 traveler's, 74 Vibrio cholerae, 70-71 Glutamic acid decarboxylase, antibodies to, Vibrio parahaemolyticus, 70-71 in diabetes mellitus, 501-502, 506 viral, 72-74 Glyburide, failure of, 543, 546-547 Yersinia enterocolitica, 72 Glycemic control agents, oral. See Oral Gastroplasty, for obesity, in diabetes hypoglycemic agents: specific agents mellitus, 478-481 Glycemic index, in diabetes mellitus diet Gatifloxacin, for gonorrhea, 194 planning, 585 Gemfibrozil, for dyslipidemia, 647-648, Gonadotropin-secreting pituitary tumors, 650-651. 656-658, 661 765, 777-77 Gender differences Gonorrhea, in females, 193-194 in body composition, 258-260 in obesity prevalence, 269-271 Gotu kola (caffeine), for weight loss, in herbal preparations, 441-449 Genetic factors in Otitis media, 111 Granulomas, in nontuberculous in pheochromocytoma, 804-805 mycobacterial infections, 14 Genital tract infections Graves disease. subclinical, 632-634 in females, 189-199 Green tea catechins, for obesity, 449-450 Chlamydia trachomatis, 192-193 endometritis, 197-198 Griseofulvin, for tinea infections, 17 gonorrhea, 193-194 herpes simplex virus, 196-197 Growth hormone human papillomavirus, 194-196 for Prader-Willi syndrome, 367 salpingitis, 197-198 measurement of, in growth vaginitis, 189-192 hormone-producing pituitary in men, 169-188 tumors, 773 35 9975 pituitary tumors secreting, 7 Genital warts, 180-183, 194-196 clinical features of, 772-773 laboratory tests for, 773 Genitourinary symptoms, in menopause, radiography in, 773 hormone therapy for, 672 treatment of, 773 Gestational diabetes, 503, 538 Growth hormone-receptor antagonists, for Gingivitis, in HIV infection, 208 growth hormone-producing pituitary tumors, 776-777 Ginseng, for menopausal symptoms, 671 Guarana (caffeine), for weight loss, in Glargine, for diabetes mellitus herbal preparations, 441-449 in nothing-by-mouth situation, 554 Gynecomastia, in prolactinoma, 767, 769